Literature DB >> 23404373

Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate.

Joanna E Barbara1, Faraz Kazmi, Andrew Parkinson, David B Buckley.   

Abstract

Metabolism-dependent inhibition (MDI) of cytochrome P450 (P450) enzymes has the potential to cause clinically relevant drug-drug interactions. In the case of several alkylamine drugs, MDI of P450 involves formation of a metabolite that binds quasi-irreversibly to the ferrous heme iron to form a metabolic intermediate (MI) complex. The specific metabolites coordinately bound to ferrous iron and the pathways leading to MI complex formation are the subject of debate. We describe an approach combining heme iron oxidation with potassium ferricyanide and metabolite profiling to probe the mechanism of MI complex-based CYP3A4 inactivation by the secondary alkylamine drug lapatinib. Ten metabolites formed from lapatinib by CYP3A4-mediated heteroatom dealkylation, C-hydroxylation, N-oxygenation with or without further oxidation, or a combination thereof, were detected by accurate mass spectrometry. The abundance of one metabolite, the N-dealkylated nitroso/oxime lapatinib metabolite (M9), correlated directly with the prevalence or the disruption of the MI complex with CYP3A4. Nitroso/oxime metabolite formation from secondary alkylamines has been proposed to occur through two possible pathways: (1) sequential N-dealkylation, N-hydroxylation, and dehydrogenation (primary hydroxylamine pathway) or (2) N-hydroxylation with dehydrogenation to yield a nitrone followed by N-dealkylation (secondary hydroxylamine pathway). All intermediates for the secondary hydroxylamine pathway were detected but the primary N-hydroxylamine intermediate of the primary hydroxylamine pathway was not. Our findings support the mechanism of lapatinib CYP3A4 inactivation as MI complex formation with the nitroso metabolite formed through the secondary hydroxylamine and nitrone pathway, rather than by N-dealkylation to the primary amine followed by N-hydroxylation and dehydrogenation as is usually assumed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404373     DOI: 10.1124/dmd.113.051151

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

Review 1.  Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.

Authors:  Han Kiat Ho; James Chun Yip Chan; Klarissa D Hardy; Eric Chun Yong Chan
Journal:  Drug Metab Rev       Date:  2015-02-02       Impact factor: 4.518

2.  A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism?

Authors:  Yuan Wei; Chenxiao Tang; Vinayak Sant; Song Li; Samuel M Poloyac; Wen Xie
Journal:  Curr Pharmacol Rep       Date:  2016-05-04

3.  Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.

Authors:  Joanna K Towles; Rebecca N Clark; Michelle D Wahlin; Vinita Uttamsingh; Allan E Rettie; Klarissa D Jackson
Journal:  Drug Metab Dispos       Date:  2016-07-22       Impact factor: 3.922

4.  Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.

Authors:  Klarissa D Hardy; Michelle D Wahlin; Ioannis Papageorgiou; Jashvant D Unadkat; Allan E Rettie; Sidney D Nelson
Journal:  Drug Metab Dispos       Date:  2013-11-04       Impact factor: 3.922

5.  OxaD: A Versatile Indolic Nitrone Synthase from the Marine-Derived Fungus Penicillium oxalicum F30.

Authors:  Sean A Newmister; Claire M Gober; Stelamar Romminger; Fengan Yu; Ashootosh Tripathi; Lizbeth Lorena L Parra; Robert M Williams; Roberto G S Berlinck; Madeleine M Joullié; David H Sherman
Journal:  J Am Chem Soc       Date:  2016-08-24       Impact factor: 15.419

6.  Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.

Authors:  Jennifer E Bissada; Vivian Truong; Arsany A Abouda; Kahari J Wines; Rachel D Crouch; Klarissa D Jackson
Journal:  Drug Metab Dispos       Date:  2019-09-06       Impact factor: 3.922

7.  Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.

Authors:  Justin D Lutz; Brooke M VandenBrink; Katipudi N Babu; Wendel L Nelson; Kent L Kunze; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2013-06-19       Impact factor: 3.922

Review 8.  Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity.

Authors:  Gabriel Tao; Junqing Huang; Bhagavatula Moorthy; Cathryn Wang; Ming Hu; Song Gao; Romi Ghose
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-09-02       Impact factor: 4.481

9.  Structure, In Vivo Detection, and Antibacterial Activity of Metabolites of SQ109, an Anti-Infective Drug Candidate.

Authors:  Satish R Malwal; Matthew D Zimmerman; Nadine Alvarez; Jansy P Sarathy; Véronique Dartois; Carol A Nacy; Eric Oldfield
Journal:  ACS Infect Dis       Date:  2021-07-19       Impact factor: 5.084

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.